1. A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Issue 5 (2nd July 2018) Authors: El Sharkawy, R.; Thabet, K.; Lampertico, P.; Petta, S.; Mangia, A.; Berg, T.; Metwally, M.; Bayoumi, A.; Boonstra, A.; Brouwer, W. P.; Smedile, A.; Abate, M. L.; Loglio, A.; Douglas, M. W.; Khan, A.; Santoro, R.; Fischer, J.; Leeming, D. J.; Liddle, C.; George, J. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 5(2018) Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long‐term analogue therapy for hepatitis B. Issue 4 (19th June 2018) Authors: Loglio, A.; Iavarone, M.; Grossi, G.; Viganò, M.; Rumi, MG.; Facchetti, F.; Lunghi, G.; Sangiovanni, A.; Colombo, M.; Lampertico, P. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 4(2018) Page Start: 431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B. Issue 1 (16th February 2017) Authors: Galmozzi, E.; Facchetti, F.; Grossi, G.; Loglio, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 49:Issue 1(2017)Supplement Page Start: e29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. High rates of renal tubular damage in HBV monoinfected patients long-term treated with tenofovir: A cross-sectional, single center, real-life study in 414 patients. Issue 1 (16th February 2017) Authors: Grossi, G.; Loglio, A.; Facchetti, F.; Galmozzi, E.; Colombo, M.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 49:Issue 1(2017)Supplement Page Start: e9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Minimal increases of alpha-fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: A 7-year longitudinal cohort study in 225 patients. Issue 1 (16th February 2017) Authors: Loglio, A.; Grossi, G.; Iavarone, M.; Viganò, M.; Sangiovanni, A.; Colombo, M.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 49:Issue 1(2017)Supplement Page Start: e28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients. Issue 1 (16th February 2017) Authors: Viganò, M.; Grossi, G.; Loglio, A.; Cappelletti, M.; Zaltron, S.; Castelli, F.; Andreone, P.; Messina, V.; Ganga, R.; Coppola, N.; Marrone, A.; Russello, M.; Marzano, A.; Taliani, G.; Fasano, M.; Fagiuoli, S.; Villa, E.; Bronte, F.; Santantonio, T.; Brancaccio, G. Journal: Digestive and liver disease Issue: Volume 49:Issue 1(2017)Supplement Page Start: e37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and efficacy of up to 76 weeks 10 mg/day (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis. (February 2020) Authors: Loglio, A.; Ferenci, P.; Schlund, F.; Tham, C.Y.L.; van Bömmel, F.; Renteria, SC. Uceda; Borghi, M.; Holzmann, H.; Perbellini, R.; Trombetta, E.; Giovanelli, S.; Porretti, L.; Prati, D.; Ceriotti, F.; Lunghi, G.; Bertoletti, A.; Urban, S.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated hbv cirrhotics treated with nuc for 10 years. (February 2020) Authors: Galmozzi, E.; Loglio, A.; Facchetti, F.; Iavarone, M.; Borghi, M.; Viganò, M.; Perbellini, R.; Rumi, M.G.; Sangiovanni, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients. (February 2020) Authors: Viganò, M.; Loglio, A.; Cerini, F.; Farina, E.; Facchetti, F.; Perbellini, R.; Rumi, M.G.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Long-term effective oral therapy could spare endoscopic surveillance of esophageal varices in HBV compensated cirrhotics: a 10-year study. (March 2021) Authors: Farina, E.; Loglio, A.; Tosetti, G.; Viganò, M.; Gentile, C.; Perbellini, R.; Borghi, M.; Facchetti, F.; Renteria, SC. Uceda; Rumi, MG.; Primignani, M.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 53:(2021)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗